NRIX Nurix Therapeutics Inc
Company Analysis
Latest News
🔴 Nurix Therapeutics is trading 5.3% down today in after-hours trading with no clear catalyst
Nurix Therapeutics is trading 5.3% down at $23.80 in after-hours trading with no clear catalyst, slipping from a regular-session close of $25.12. * There is...
🟢 Nurix Therapeutics is trading 4.1% up today amid a broader risk-on market rally
Nurix Therapeutics is trading 4.1% up at $24.18 on solid intraday gains, appearing to track a broader risk-on rally as major U.S. indices climb more than...
🔴 Nurix Therapeutics is trading 5.1% down today after Q2 earnings miss and profit-taking
Nurix Therapeutics is trading 5.1% down today at $21.89 as investors digest its recent Q2 2026 loss and revenue miss. This pullback also reflects profit-taking...
🔴 Nurix Therapeutics is trading 5.2% down today as investors lock in gains after Roche deal rally
Nurix Therapeutics is trading 5.2% down today at $23.40 as investors digest valuation and lock in gains following a sharp post-earnings and Roche-deal...
Nurix Therapeutics second quarter 2026 report highlighted by a new $2.3 billion collaboration with Roche for its lead drug, bexobrutideg.
Nurix Therapeutics reported second quarter revenue of $9.0 million and a net loss of $0.81 per share. The quarter was defined by the announcement of a...
Nurix Therapeutics Inc Q2 2026 Earnings Preview: What Analysts Expect on July 08, 2026
Nurix Therapeutics is expected to report Q2 2026 revenue of $18.52 million and a loss of $0.73 per share, while the current $28.45 stock price remains...
🟢 NRIX is trading 4.1% up today on continued Roche collaboration enthusiasm
NRIX is trading 4.1% up at $24.82 as investors continue to bid the stock higher following its high-value collaboration with Roche. • Under the global deal,...
🟢 NRIX is trading 4.4% up today on continued Roche collaboration momentum
NRIX is trading at $24.90 (+4.40%) in pre-market as investors continue to react to the strategic collaboration with Roche announced on June 8, 2026. • The...
🟢 NRIX is trading 4.3% up today after a landmark Roche collaboration
NRIX is trading 4.3% up today at $23.88 as investors continue to react to a newly announced global collaboration with Roche for the BTK degrader...
🟢 NRIX makes sharp 12.9% jump
NRIX is trading at $21.79, up 12.9% versus the comparison close of $19.30 during regular trading. This is a price-movement alert; no separate company-specific...
🟢 NRIX is trading 10.6% up today on Roche blood cancer deal optimism and bullish analyst ratings
NRIX is trading 10.6% up at $21.35 as investors continue to bid up the stock on optimism surrounding its multi-billion-dollar Roche blood cancer collaboration...
🟢 NRIX is trading 5% up today on Roche collaboration momentum and bullish analyst ratings
NRIX is trading 5% up today at $19.81 as the stock continues its multi-week rally following a major multi-billion-dollar collaboration with Roche focused on...
🟢 Nurix Therapeutics Inc is trading 5% up today extending a multi-day rebound amid bullish analyst sentiment
Nurix Therapeutics Inc is trading 5% up today at $18.43, extending a strong multi-day rebound that began after last week’s double-digit gain. • The stock...
General Atlantic Takes $93 Million Nurix Stake, Its 9th Largest Holding
General Atlantic L.P. purchased 4,897,159 shares of Nurix Therapeutics, Inc. The investment is valued at approximately $92.9 million. This acquisition gives...
🟢 Nurix Therapeutics Inc is trading 5.1% up today, extending gains on clinical trial progress and insider activity
Nurix Therapeutics Inc is trading at $17.94 (up 5.1%), extending gains from last week’s rally as momentum continues to build around the company's recent...
🟢 Nurix Therapeutics Inc makes sharp 11.1% jump
NRIX is trading at $18.86, up 11.1% versus the comparison close of $16.98 during regular trading. This is a price-movement alert; no separate company-specific...
🟢 Nurix Therapeutics Inc is trading 5.1% up today as rally extends on 93% blood cancer drug response rate
Nurix Therapeutics Inc is trading 5.1% up today at $17.84, extending a sharp rally driven by breakthrough clinical data for its lead blood cancer treatment. •...
Nurix's Blood Cancer Drug Posts 93% Response Rate — But Can a $1.5 Billion Biotech Turn Promising Data Into Real Revenue?
Shares jumped 7.1% to $16.39 as Nurix Therapeutics unveiled updated trial results for its lead cancer drug at the European Hematology Association Congress in...
🟢 Nurix Therapeutics Inc makes sharp 10.2% jump
NRIX is trading at $16.86, up 10.2% versus the comparison close of $15.30 during regular trading. This is a price-movement alert; no separate company-specific...
🟢 Nurix Therapeutics Inc is trading 7.1% up today after reporting high response rates in Phase 1 leukemia trial
Nurix Therapeutics Inc is trading at $16.39 (7.1% up) after releasing updated Phase 1a/1b data for its BTK degrader bexobrutideg (NX-5948) in relapsed or...